The agrochemical field has long relied on animal models to evaluate the safety and efficacy of substances, but there’s a growing demand to adopt new alternative methods (NAMs) that can further the industry while reducing the need for animal testing. However, questions remain as to their long-term viability.

Join Robert Landsiedel, Vice President of Experimental Toxicology and Ecology, and Susanne Kolle, Research Coordinator of Experimental Toxicology and Ecology at BASF, as they explain the benefits of NAMs, how they comply with the 3Rs principle, and the role collaboration is playing to push NAMs as a viable alternative to animals.

Show Notes

Alternative Methods

AMAP Strategic Partnerships

Animals in Research

Modernizing Drug Development

Agrochemical Testing Service for Approvals

Chemical Testing Services

Charles River Laboratories Announces Development of Nonclinical Virtual Control Groups with Sanofi to Reduce the Use of Animals

Charles River Laboratories, in Collaboration with MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives

How can genetic, geographic, and social considerations effect outcomes for Black women with cancer? To answer this question, I am joined this week by Dr. Lauren E. McCullough, Associate Professor in the Department of Epidemiology at the Rollins School of Public Health, and Julia Schueler, Research Director Therapeutic Area Lead Oncology for Charles River. Dr. McCullough is also one of the lead researchers for the American Cancer Society’s VOICES of Black Women initiative, which will track the health of participants over several years to gain insight into health considerations for Black women. For more information on how to enroll, please visit voices.cancer.org.

The N=1 Collaborative is changing the way we view drug development. Their specialty is creating customized therapies tailored to individual patients, paving the way for a unique approach that can leave long-lasting impacts on those with ultra-rare diseases.

Join us as Executive Director Hugh Hempel discusses the origins of N=1, the collaborative effort it takes to advance customized therapies down the pipeline, and what the future holds for the field of individualized medicine.

Show Notes

n=1 Collaborative

Rare Disease | Charles River

Rare Disease Research for Drug Development

Repurposing Drugs for Rare Disease

S4 E07: Free For Life: The Story of N-Lorem Foundation